WO1999024431A1 - Process for preparing a chiral nucleoside analogue - Google Patents
Process for preparing a chiral nucleoside analogue Download PDFInfo
- Publication number
- WO1999024431A1 WO1999024431A1 PCT/EP1997/006379 EP9706379W WO9924431A1 WO 1999024431 A1 WO1999024431 A1 WO 1999024431A1 EP 9706379 W EP9706379 W EP 9706379W WO 9924431 A1 WO9924431 A1 WO 9924431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- amino
- methanol
- cyclopropylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Definitions
- the present invention relates to a new process for the preparation of the chiral nucleoside analogue (1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H purin-9-yl]-2- cyclopentene-1-methanol (compound of Formula (I)).
- the compound of formula (I) is described as having potent activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in EPO34450.
- WO91/15490 discloses a single step process for the formation of the (1S, 4R)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1- methanol intermediate by reacting (1S, 4R)-4-hydroxy-2-cyclopentene-1 -methanol, in which the allylic hydroxyl group has been activated as an ester or carbonate and the other hydroxyl group has a blocking group attached (for example 1 ,4- bis- methylcarbonate) with 2-amino-6-chloropurine.
- This process offers significant cost savings compared to previous processes described and represents the first aspect of the present invention.
- the major commercial advantages are the length of time to manufacture the compound of formula (I) is significantly reduced using the process of the invention compared to earlier processes described, and wastage is significantly reduced.
- X is H or a blocking group and Y is H or an activating group, with 2- amino-6-(cyclopropylamino) purine in the presence of a catalyst.
- X is H or a blocking group and Y is H or an activating group, with 2-amino- 6-(cyclopropylamino) purine.
- An optional further step is resolving the product of the invention to a compound of formula (I) substantially free of the corresponding enantiomer.
- 2-Amino-6-cyclopropylamino-9H-purine can be prepared by treating 2-amino-6- chloropurine with cyclopropylamine, or in accordance with the methods described in US5420115.
- (1S, 4R)- 4-Hydroxy-2-cyclopentene-1 -methanol and the activated and/or blocked version of (1S, 4R)-4-hydroxy-2-cyclopentene-1-methanol may be prepared in accordance with reactions described in WO91/15490 or Hodgson et al. in J.Chem. Soc. Perkin Trans. 1 1994; 3373-3378..
- the preferred catalyst is a transition metal catalyst, preferably a palladium compound but may also be a derivative of other transition metals (such as nickel, molybdenum, tungsten), preferably in the presence of a ligand such as a phosphine.
- a transition metal catalyst preferably a palladium compound but may also be a derivative of other transition metals (such as nickel, molybdenum, tungsten), preferably in the presence of a ligand such as a phosphine.
- Preferred transition metal catalyst are tetrakis (triphenylphosphine) palladium, or tris(dibenzylideneacetone) dipalladium, in the presence of triphenylphosphine
- Suitable activated derivatives of the allylic alcohol group of the compound of formula (II) or (III) include esters (such as acetate); carbonates (such as methylcarbonate); carbamates, preferably RR 'NOC wherein R and R 1 independently selected from C1-6alkyl, aryl or heteroaryl; or phosphates, preferably (RO) 2 OP wherein each R is independently selected from C1-6alkyl, aryl and heteroaryl.
- the allylic alcohol may be activated in situ by the addition of a metal salt, for example stannous chloride (see, for example, Y. Masuyama et al, Chem.Lett. 1995 p. 1121 and references contained therein).
- a metal salt for example stannous chloride (see, for example, Y. Masuyama et al, Chem.Lett. 1995 p. 1121 and references contained therein).
- a base such as sodium hydride or cesium carbonate may optionally be added, particularly where the activated derivative is a simple ester such as acetate.
- a preferred activng blocking groups are cylic carbonates (such as used for the compound of formula (IV).
- Suitable blocking groups may be any such groups recognised in the art of organic chemistry as suitable for protecting primary hydroxymethyl groups, suitable blocking groups include those reported by T W Green in Protecting Groups in Organic Synthesis, Chapter 7, page 10. J. Wiley and sons, New York, 1981 , and include esters, ethers and carbonates (such as methyl carbonate).
- Suitable solvents include, for example, dimethylsulphoxide, N.N- dimethylformamide, N.N-dimethylacetamide or tetrahydrofuran preferably at temperatures between 0° and 150°C.
- Triphenylphosphine 14mg was added, under nitrogen, to a mixture of (1S.4R)- 4-hydroxy-2-cyclopentene -1 -methanol bis(methylcarbonate) (91 mg), 2-amino-6- (cyclopropylamino) purine (90mg), tris(dibenzylideneacetone)dipalladium (12mg) and dry DMF (2ml) and the resulting solution stirred at room temperature for 40 min.
- the DMF was removed at 60° in vacuo and the residue partitioned between ethyl acetate (25ml.) and 20% sodium chloride solution (10ml.).
- the ethyl acetate solution was washed with 20% sodium chloride (2x12ml.) and with saturated sodium chloride solution, then dried (MgSO ) and the solvent removed in vacuo.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A new process for the preparation of the chiral nucleoside analogue (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H purin-9-yl]-2-cyclopentene-1-methanol comprising reacting a compound of formula (II) or (III), wherein X is H or a blocking group and Y is H or an activating group, with 2-amino-6-(cyclopropylamino)purine in the presence of a catalyst.
Description
PROCESS FOR PREPARING A CHIRAL NUCLEOSIDE ANALOGUE
The present invention relates to a new process for the preparation of the chiral nucleoside analogue (1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H purin-9-yl]-2- cyclopentene-1-methanol (compound of Formula (I)).
The compound of formula (I) is described as having potent activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in EPO34450.
(I)
Results presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (October 4-7, 1994) demonstrate that the compound of formula I has significant activity against HIV comparable to, and if not better than, some current anti HIV drugs, such as zidovudine and didanosine.
Currently the compound of Formula (I) is undergoing clinical investigation to determine its safety and efficacy in humans. Therefore, there exists at the present time a need to supply large quantities of this compound for use in clinical trials.
Current routes of synthesising the compound of formula (I) involve multiple steps and are relatively expensive. It will be noted that the compound has two centres of asymmetry and it is essential that any route produces the compound of formula (I) substantially free of the corresponding enantiomer, preferably the compound of formula (I) is greater than 95% w/w free of the corresponding enantiomer.
Processes proposed for the preparation of the compound of formula (I) generally start from a pyrimidine compound, coupling with a 4-amino-2-cyclopentene-1- methanol analogue, cyclisation to form the imidazole ring and then introduction of
the cyclopropylamine group into the 6 position of the purine, such routes include those suggested in EPO434450 and WO9521161. Essentially both routes disclosed in the two prior patent applications involve the following steps:-
(i) coupling (1S, 4R)-4-amino-2-cyclopentene-1-methanol to N-(4,6-dichloro-5- formamido-2-pyrimidinyl) acetamide or a similar analogue thereof, for example N- (2-amino-4,6-dichloro-5-pyrimidinyl) formamide;
(ii) ring closure of the resultant compound to form the intermediate (1 S, 4R)-4- (2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1 -methanol;
(iii) substituting the halo group by a cyclopropylamino group on the 6 position of the purine ring.
The above routes are multi-step processes. By reducing the number of processing steps significant cost savings can be achieved due to the length of time to manufacture the compound being shortened and the waste streams minimised.
An alternative process suggested in the prior art involves the direct coupling of carbocyclic ribose analogues to the N atom on the 9 position of 2-amino-6-chloro purine. For example WO91/15490 discloses a single step process for the formation of the (1S, 4R)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1- methanol intermediate by reacting (1S, 4R)-4-hydroxy-2-cyclopentene-1 -methanol, in which the allylic hydroxyl group has been activated as an ester or carbonate and the other hydroxyl group has a blocking group attached (for example 1 ,4- bis- methylcarbonate) with 2-amino-6-chloropurine.
However we have found that when synthesising (1S, 4R)-4-(2-amino-6-chloro-9H- purin-9-yl)-2-cyclopentene-1- methanol by this route a significant amount of an N- 7 isomer is formed (i.e. coupling has occurred to the nitrogen at the 7- position of the purine ring) compared to the N-9 isomer desired. Further steps are therefore required to convert the N-7 product to the N-9 product, or alternatively removing the N-7 product, adding significantly to the cost.
We have found that by using a transition metal catalysed process for the direct coupling of a compound of formula (II) or (III),
wherein X is H or a blocking group and Y is H or an activating group, with 2-amino- 6-(cyclopropylamino)purine, the compound of formula (I) is produced in excellent yield and with excellent N9-selectivity.
This process offers significant cost savings compared to previous processes described and represents the first aspect of the present invention. The major commercial advantages are the length of time to manufacture the compound of formula (I) is significantly reduced using the process of the invention compared to earlier processes described, and wastage is significantly reduced.
Accordingly presented as the first feature of the present invention is a process for the preparation of a compound of formula (I) comprising reacting a compound of formula (II) or (III),
wherein X is H or a blocking group and Y is H or an activating group, with 2- amino-6-(cyclopropylamino) purine in the presence of a catalyst.
It will be understood that the process described above could also be used where the compound of formula (II) or (III) used is a mixture of enantiomers, particularly a racemic mixture, and that the compound formed would be a mixture of enantiomers of the compound of formula (I). The mixture of enantiomers of the compound of formula (I) may then be resolved to the compound of formula (I) by chiral chromatographic techniques or by reaction with stereoselective enzymes, for
example esterifying the compound of formula (I) and resolving by processing with an esterase, as described in EP 034450.
Therefore accordingly presented as a second feature of the invention is a process for the preparation of a mixture of enantiomers of a compound of formula (I) comprising reacting a mixture of enantiomer of a compound of formula (II) or (III),
wherein X is H or a blocking group and Y is H or an activating group, with 2-amino- 6-(cyclopropylamino) purine. An optional further step is resolving the product of the invention to a compound of formula (I) substantially free of the corresponding enantiomer.
2-Amino-6-cyclopropylamino-9H-purine can be prepared by treating 2-amino-6- chloropurine with cyclopropylamine, or in accordance with the methods described in US5420115.
(1S, 4R)- 4-Hydroxy-2-cyclopentene-1 -methanol and the activated and/or blocked version of (1S, 4R)-4-hydroxy-2-cyclopentene-1-methanol may be prepared in accordance with reactions described in WO91/15490 or Hodgson et al. in J.Chem. Soc. Perkin Trans. 1 1994; 3373-3378..
(1 R,2R)-2-Hydroxy-3-cyclopentene-1 -methanol may be prepared in accordance with the procedures described in WO92/18444.
The preferred catalyst is a transition metal catalyst, preferably a palladium compound but may also be a derivative of other transition metals (such as nickel, molybdenum, tungsten), preferably in the presence of a ligand such as a phosphine. Preferred transition metal catalyst are tetrakis (triphenylphosphine) palladium, or tris(dibenzylideneacetone) dipalladium, in the presence of triphenylphosphine
Suitable activated derivatives of the allylic alcohol group of the compound of formula (II) or (III) include esters (such as acetate); carbonates (such as methylcarbonate); carbamates, preferably RR 'NOC wherein R and R1 independently selected from C1-6alkyl, aryl or heteroaryl; or phosphates, preferably (RO)2OP wherein each R is independently selected from C1-6alkyl, aryl and heteroaryl. Alternatively the allylic alcohol may be activated in situ by the addition of a metal salt, for example stannous chloride (see, for example, Y. Masuyama et al, Chem.Lett. 1995 p. 1121 and references contained therein).
A base such as sodium hydride or cesium carbonate may optionally be added, particularly where the activated derivative is a simple ester such as acetate.
For the compound of formula (III) a preferred activitating blocking groups are cylic carbonates (such as used for the compound of formula (IV).
Suitable blocking groups may be any such groups recognised in the art of organic chemistry as suitable for protecting primary hydroxymethyl groups, suitable blocking groups include those reported by T W Green in Protecting Groups in Organic Synthesis, Chapter 7, page 10. J. Wiley and sons, New York, 1981 , and include esters, ethers and carbonates (such as methyl carbonate).
Suitable solvents include, for example, dimethylsulphoxide, N.N- dimethylformamide, N.N-dimethylacetamide or tetrahydrofuran preferably at temperatures between 0° and 150°C.
Glossary
The following abbreviations are used:
DMF = N, N-dimethyl formamide DMSO = dimethyl sulfoxide
Example 1 (1 S, 4R)-4-[2-Amino-6-(cyclopropylamino)-9H purin-9-yl]-2-cyclopentene-1- methanol
Triphenylphosphine (14mg) was added, under nitrogen, to a mixture of (1S.4R)- 4-hydroxy-2-cyclopentene -1 -methanol bis(methylcarbonate) (91 mg), 2-amino-6- (cyclopropylamino) purine (90mg), tris(dibenzylideneacetone)dipalladium (12mg) and dry DMF (2ml) and the resulting solution stirred at room temperature for 40 min.
The DMF was removed at 60° in vacuo and the residue partitioned between ethyl acetate (25ml.) and 20% sodium chloride solution (10ml.). The ethyl acetate solution was washed with 20% sodium chloride (2x12ml.) and with saturated sodium chloride solution, then dried (MgSO ) and the solvent removed in vacuo.
The residue was dissolved in methanol (10ml.), potassium carbonate (17mg) added and the mixture stirred under nitrogen for 15h.
The solvent was removed in vacuo and the residue chromatographed on silica gel
(Merck 9385), eluting with dichloromethane-methanol [(95:5) increasing to (90:10)] to give the title compound (53mg) as a cream foam.
δ(DMSO-d6): 7.60 (s,1H); 7.27 (s,1H); 6.10 (dt,1H); 5.86 (dt, 1H); 5.81 (s,2H); 5.39 (m,1H); 4.75 (t,1H); 3.44 (t,2H); 3.03 (m, 1H): 2.86 (m,1H);2.60 (m,1H); 1.58 (dt, 1 H); 0.65 (m, 2H); 0.57 (m,2H).
TLC SiO2/CHCI3-MeOH (4:1) Rf 0.38; det. U.V., KMnO4
Example 2
(1S, 4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1- methanol
A stirred mixture of 2-amino-6-(cyclopropylamino)purine (100mg) and cesium carbonate (175mg) in dry DMSO (5ml) was heated at 60° under nitrogen for 2h. The mixture was cooled to room temperature then tetrakis(triphenylphosphine) palladium (85mg) and a solution of (1S,4R)-4-hydroxy-2-cyclopentene-1 -methanol diacetate (79mg) in DMSO (1ml) were added. The mixture was then heated at 65° for 2.25h.
Methanol (10ml) and potassium carbonate (210mg) were added and the mixture stirred at 40° for 45min, after which the solid was filtered off on Celite and the filtrate evaporated to low volume at 90° in vacuo. The residual gum was triturated with dichloromethane (2x10ml) and the resulting brown solid residue chromatographed in silica gel (Merck 9385), eluting with dichloromethane- methanol (9:1) to give the title compound (26mg) as a yellow foam, identical by NMR to the product of Example 1. Tic SiO2/CHCI3-MeOH (4:1) Rf 0.38; det U.V., KMnO4
Example 3
(1S, 4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1- methanol
A stirred mixture of 2-amino-6-(cyclopropylamino)purine (1.00g) and cesium carbonate (1.75 g) in dry DMSO (50 ml_) was heated at 60°c under nitrogen for 2 h. The mixture was cooled to room temperature then tetrakis(triphenylphosphine) palladium (0.85 g) and a solution of (1R,2R)-2-hydroxy-3-cyclopentene-1- methanol diacetate (0.79 g) in DMSO (10 ml_) was added. The mixture was heated at 65°C for 2.5 h then allowed to cool to room temperature overnight. Methanol (100 mL) and potassium carbonate (2.10 g) were added and the mixture was stirred at 40°C for 1 h after which the mixture was filtered through Celite. The filtrate was evaporated to low volume at 90°C in vacuo to give a brown oil. Dichloromethane (2x100 ml) was added to the oil and evaporated. The resulting crude oil was chromatographed on silica gel (eiution with dichloromethane- methanol (9:1)) to give the title compound as a yellow foam (0.12 g), identical by NMR to the product of Example 1. TLC: (silica gel, methylene chloride/methanol 9/1 (v/v); Rf = 0.45. Rf of reference product, 0.45).
Claims
A process for the preparation of a compound of formula (I)
comprising reacting a compound of formula (II) or (III),
wherein X is H or a blocking group and Y is H or an activating group, with 2-amino-6-(cyclopropylamino) purine in the presence of a transition metal catalyst.
A process for the preparation of a mixture of enantiomers of a compound of formula (I)
3. A process as claimed in claim 1 or 2 wherein the activating group is selected from : a carbonate; a cyclic carbonate; a carbamate; and a phosphate ester.
4. A process as claimed in claim 3 wherein the activating group is methyl carbonate.
5. A process as claimed in claim 1 or 2 wherein the activation of the allylic hydroxyl group is achieved by the addition of a metal salt.
6. A process as claimed in any claim from 1 to 5 wherein the transition metal catalyst is a palladium (0) complex.
7. A process as claimed in claim 6 wherein the transition metal catalyst is tetrakis(triphenylphosphine)palladium or tris(dibenzylideneacetone)dipalladium in the presence of triphenylphosphine.
Example 4
2-Amino-6-cyclopropylamino-9H-purine
A suspension of 2-amino-6-chloropurine (5.0g) in methanol (15ml) was treated with cyclopropylamine (12.5ml). The suspension was heated at reflux for 28h. The resultant solution was allowed to cool to 40┬░C and was evaporated in vacuo to give a yellow-orange foam. The foam was dissolved in isopropanol (200ml) and methanol (50ml) and stirred with potassium carbonate (5.0g). The suspension was cooled to 0-5┬░C and stirred for 30 minutes. The suspension was filtered, the filtrate was evaporated and the residue was dried in a vacuum oven at 45┬░C for 64h to give an orange foam (7.11g). A portion of this foam (1.0g) was recrystallised from acetonitriie (10ml) and isopropanol (1.0ml). The solid was isolated by filtration and dried in a vacuum oven at 45┬░C to give a pale orange solid (0.622g).
╬┤ (DMSO-d6): 7.61 (s, 1H); 7.15 (s, 1 H); 5.6 (s,2H); 3.01 (m, 1H); 0.52-0.70 (m, 4H) M.Pt. 150-152┬░C.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1997/006379 WO1999024431A1 (en) | 1997-11-12 | 1997-11-12 | Process for preparing a chiral nucleoside analogue |
| AU56534/98A AU5653498A (en) | 1997-11-12 | 1997-11-12 | Process for preparing a chiral nucleoside analogue |
| EP97952769A EP1032573A1 (en) | 1997-11-12 | 1997-11-12 | Process for preparing a chiral nucleoside analogue |
| JP2000520442A JP2001522850A (en) | 1997-11-12 | 1997-11-12 | Methods for producing chiral nucleoside analogs |
| NO20002168A NO20002168L (en) | 1997-11-12 | 2000-04-27 | Method of Preparation of Chiral Nucleoside Analogs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1997/006379 WO1999024431A1 (en) | 1997-11-12 | 1997-11-12 | Process for preparing a chiral nucleoside analogue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999024431A1 true WO1999024431A1 (en) | 1999-05-20 |
Family
ID=8166798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/006379 WO1999024431A1 (en) | 1997-11-12 | 1997-11-12 | Process for preparing a chiral nucleoside analogue |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1032573A1 (en) |
| JP (1) | JP2001522850A (en) |
| AU (1) | AU5653498A (en) |
| WO (1) | WO1999024431A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421819A1 (en) * | 1989-10-06 | 1991-04-10 | The Wellcome Foundation Limited | Therapeutic nucleosides |
| EP0434450A2 (en) * | 1989-12-22 | 1991-06-26 | The Wellcome Foundation Limited | Therapeutic nucleosides |
| WO1991015490A1 (en) * | 1990-04-06 | 1991-10-17 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
| WO1995021161A1 (en) * | 1994-02-04 | 1995-08-10 | The Wellcome Foundation Limited | Chloropyrimide intermediates |
-
1997
- 1997-11-12 JP JP2000520442A patent/JP2001522850A/en active Pending
- 1997-11-12 WO PCT/EP1997/006379 patent/WO1999024431A1/en not_active Application Discontinuation
- 1997-11-12 EP EP97952769A patent/EP1032573A1/en not_active Withdrawn
- 1997-11-12 AU AU56534/98A patent/AU5653498A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0421819A1 (en) * | 1989-10-06 | 1991-04-10 | The Wellcome Foundation Limited | Therapeutic nucleosides |
| EP0434450A2 (en) * | 1989-12-22 | 1991-06-26 | The Wellcome Foundation Limited | Therapeutic nucleosides |
| WO1991015490A1 (en) * | 1990-04-06 | 1991-10-17 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
| WO1995021161A1 (en) * | 1994-02-04 | 1995-08-10 | The Wellcome Foundation Limited | Chloropyrimide intermediates |
Non-Patent Citations (1)
| Title |
|---|
| N.KATAGIRI ET AL.: "Efficient Synthesis of Carbovir and its Congener via pi-allylpalladium Complex Formation by Ring Strain-Assisted C-N Bond Cleavage.", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 62, no. 6, 21 March 1997 (1997-03-21), pages 1580 - 1581, XP002064209 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1032573A1 (en) | 2000-09-06 |
| AU5653498A (en) | 1999-05-31 |
| JP2001522850A (en) | 2001-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2167345A1 (en) | 2,8-disubstituted quinazolinones | |
| CA2307951A1 (en) | Process for the synthesis of nucleoside analogs | |
| Siddiqi et al. | Enantiospecific synthesis of 5′-noraristeromycin and its 7-deaza derivative and a formal synthesis of (-)-5′-homoaristeromycin | |
| US5126452A (en) | Synthesis of purine substituted cyclopentene derivatives | |
| KR100701114B1 (en) | Process for the production of purine derivatives and intermediates therefor | |
| Mekonnen et al. | Synthesis and antimalarial activities of base-catalyzed adducts of 11-azaartemisinin | |
| WO1999021861A1 (en) | Process for preparing a chiral nucleoside analogue | |
| AU3760793A (en) | Antiviral phosphonic acid derivatives of purine analogues | |
| EP1032573A1 (en) | Process for preparing a chiral nucleoside analogue | |
| CN102532199A (en) | Structure and synthesis of novel benzyl amido phosphate prodrug of nucleoside compound | |
| Szakonyi et al. | Carbocyclic nucleosides from enantiomeric, α-pinane-based aminodiols | |
| US5057630A (en) | Synthesis of cyclopentene derivatives | |
| Huang et al. | Synthesis of the minor acrolein adducts of 2′-deoxyguanosine and their generation in oligomeric DNA | |
| Boryski | A facile synthesis of 9-(1, 3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) from guanosine | |
| US6437125B1 (en) | Process for the production of purine derivatives | |
| EP1456211A1 (en) | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | |
| EP0564006A2 (en) | Process for preparing purine derivatives and novel purine derivatives | |
| Sagi et al. | Synthesis and enzymic activity of some new purine ring system analogs of adenosine 3'5'-cyclic monophosphate | |
| US5079364A (en) | T-alkyl ergoline derivatives | |
| Vince et al. | 6-Deoxycarbovir: a xanthine oxidase activated prodrug of carbovir | |
| KR20190002779A (en) | Regioselective and stereoselective preparation method of N-glycoside compounds using metal catalysts from alkoxyallene compounds | |
| US5241069A (en) | Carbonate intermediates for the synthesis of purine substituted cyclopentene derivatives | |
| US4690917A (en) | Imidazopyridayine derivatives having antiviral activity | |
| Moreno‐Mañas et al. | 2, 4, 6‐Triphenylpyridine as a neutral leaving group in the palladium (0)‐catalyzed allylation of nucleophiles | |
| Curran | An Unanticipated Result in the Pd (0) Catalyzed Coupling of Sodium Adenate with cis-4-Acetyloxy-and cis-4-t-Butyldimethylsilyloxy-2-Cyclopentenyl Diethylphosphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 09530583 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1997952769 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997952769 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997952769 Country of ref document: EP |